Annexon, Inc. (NASDAQ:ANNX) Receives Consensus “Buy” Recommendation From Analysts
Annexon, Inc. (NASDAQ:ANNX) has been assigned a consensus “Buy” recommendation by the six analysts who currently cover the company, reports MarketBeat Ratings. One equity research analyst rated the stock with a sell recommendation and five gave the company a buy recommendation. The 12-month average price target among brokers who have reported on the stock in the past year is $39.00.
A number of equity research analysts have recently commented on ANNX shares. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a target price of $39.00 on Annexon shares in a research report on Tuesday, November 2. HC Wainwright began covering Annexon in a research report on Tuesday, November 30. They issued a “buy” rating and a target price of $40.00 on the stock. Cowen reiterated an “outperform” rating on Annexon shares in a Tuesday, Nov. 2, research report. Finally, Zacks Investment Research downgraded Annexon from a “held” rating to a “sell” rating in a Tuesday, January 11 report.
Shares of NASDAQ ANNX opened at $6.94 on Friday. The company’s 50-day moving average price is $10.27 and its 200-day moving average price is $15.60. The company has a market capitalization of $266.32 million, a P/E ratio of -2.28 and a beta of 0.91. Annexon has a 52-week low of $6.84 and a 52-week high of $38.01.
A number of large investors have recently changed their positions in the company. Geode Capital Management LLC increased its stake in Annexon shares by 13.0% during the 4th quarter. Geode Capital Management LLC now owns 480,208 shares of the company worth $5,517,000 after purchasing an additional 55,165 shares during the period. CNA Financial Corp increased its stake in Annexon shares by 16.5% during the 4th quarter. CNA Financial Corp now owns 19,710 shares of the company worth $226,000 after purchasing an additional 2,790 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Annexon during the 4th quarter for a value of approximately $1,159,000. Charles Schwab Investment Management Inc. increased its stake in Annexon shares by 2.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 194,952 shares of the company worth $2,240,000 after purchasing an additional 4,025 shares during the period. Finally, Ensign Peak Advisors Inc acquired a new position in Annexon stock during Q4 worth approximately $96,000.
Annexon Company Profile
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain and eye disorders. The Company’s C1q is a classical complement pathway initiator molecule that targets distinct disease processes, such as antibody-mediated autoimmune diseases and complement-mediated neurodegeneration.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Annexon right now?
Before you consider Annexon, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Annexon didn’t make the list.
Although Annexon currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here